Videos

Ping Ye, PhD, developed a machine learning model to predict 90-day mortality risk among patients with metastatic cancer, aiming to enable earlier Advance Care Planning discussions and increase hospice enrollment in a community oncology...

Mateo Banegas, PhD, MPH, presents work from an ongoing randomized controlled trial of a novel financial navigation intervention being carried out at Kaiser Permanente that aims to reduce financial hardship among newly diagnosed patients with...

Sara Tolaney, MD, MPH, discusses results from the adjuvant abemaciclib trial monarche, analyzing factors that were associated with an increased risk of treatment discontinuation among patients who had high risk hormone receptor positive,...

Patrick Bliven, MD, discusses report patterns and therapy utilization in patients with relapsed/refractory diffuse large B-cell lymphoma, comparing overall survival among double-hit lymphoma (DHL) and non-DHL subgroups for chimeric antigen...

Robert Coleman, MD, discusses results from a real-world evidence trial, evaluating the efficacy of dostarlimab among patients with tumors deficient in MMR.

Gordon Kuntz sits down with Carole Tremonti, RN, MBA, of Project Ronin to discuss clinical decision support and artificial intelligence and their role in cancer care.

Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.

Marcelo Capra, MD, discusses results from a study comparing the benefit of progression-free survival associated with isatuximab in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone among patients with relapsed...

Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...

Puneeth Indurlal, MD, MS, describes his study on the utilization and financial impact of abiraterone therapeutic interchange in The Network during an Oncology Care Model performance period, a value-based care program from Medicare that...